Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.87 |
| ▸ | BCHE | P06276 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979719 | 1.00 | ABCG2 (0.87) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL7186177 | 0.91 | ABCG2 (0.72) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL7186174 | 0.91 | ABCG2 (0.72) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL7185751 | 0.87 | ABCG2 (0.88) | ABCG2MAPTRAB9ACYP1A2CYP2D6 | |
| SCHEMBL7185747 | 0.87 | ABCG2 (0.88) | ABCG2MAPTRAB9ACYP1A2CYP2D6 | |
| SCHEMBL13966803 | 0.86 | ABCG2 (0.65) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL7101379 | 0.86 | ABCG2 (0.85) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL4610668 | 0.86 | ABCG2 (0.85) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL7192430 | 0.86 | ABCG2 (0.85) | ABCG2BCHENPC1MAPTRAB9A | |
| SCHEMBL4610666 | 0.86 | ABCG2 (0.85) | ABCG2BCHENPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450777-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY | ANGIOLAB INC (KR) | 2013-05-08 | — | — | EP | disclosed |
| EP-2054046-B1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER (US) | 2012-09-26 | — | — | EP | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | ABCG2 635/4885BCHE 4314/4885NPC1 1622/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | ABCG2 659/4885BCHE 4484/4885NPC1 1709/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | ABCG2 535/4885BCHE 4276/4885NPC1 1134/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | ABCG2 535/4885BCHE 4276/4885NPC1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.